209960-91-8

Basic information

• Product Name: 2-methoxy-4-morpholinoaniline
• Synonyms: 2-methoxy-4-morpholinoaniline;2-methoxy-4-morpholinoaniline dihydrochloride;2-Methoxy-4-morpholin-4-yl-phenylamine;2-methoxy-4-(4-morpholinyl)Benzenamine;2-Methoxy-4-(morpholin-4-yl)aniline;2-Methoxy-4-morpholinobenzenamine
• CAS NO: 209960-91-8
• Molecular Formula: C₁₁H₁₆N₂O₂
• Molecular Weight: 208.259
• Mol File: 209960-91-8.mol
• Article Data: 22

Chemical Properties

• Melting Point: 78-80°
• Boiling Point: 408.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.163±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 6.30±0.40(Predicted)
• CAS DataBase Reference: 2-methoxy-4-morpholinoaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methoxy-4-morpholinoaniline(209960-91-8)
• EPA Substance Registry System: 2-methoxy-4-morpholinoaniline(209960-91-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 209960-91-8(Hazardous Substances Data)

Usage

General Description

2-methoxy-4-morpholinoaniline, also known as Memantine, is a chemical compound with the molecular formula C12H17N2O. It is a pharmaceutical drug used to treat moderate to severe Alzheimer's disease and dementia. Memantine works by blocking the activity of certain receptors in the brain, specifically the N-methyl-D-aspartate (NMDA) receptors, which are involved in learning and memory. This helps to regulate the activity of glutamate, a neurotransmitter that is believed to play a role in Alzheimer's disease. Memantine is available in various forms, including oral tablets, oral solutions, and extended-release capsules, and is typically taken once or twice daily under the supervision of a healthcare professional. It has been shown to improve cognitive function and slow the progression of Alzheimer's disease in some patients. However, like any medication, Memantine may cause side effects, such as dizziness, headache, confusion, and constipation, and should only be used as directed by a doctor.

Upstream product

• 6950-88-5 4-(3-methoxy-4-nitro-phenyl)morpholine 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 175135-19-0 AMA₅₆ 
• 6627-53-8 1-chloro-3-methoxy-4-nitrobenzene 

Downstream Products

• 442548-62-1 6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (2-methoxy-4-morpholin-4-yl-phenyl)-amide 
• 1061353-83-0 2-(2-(2-methoxy-4-morpholinophenylamino)-5-(trifluoromethyl)pyridin-4-ylamino)-N,N-dimethylbenzamide trifluoroacetate 
• 1061355-73-4 2-(5-cyano-2-(2-methoxy-4-morpholinophenylamino)pyridin-4-ylamino)-N-methylbenzamide trifluoroacetate 
• 1089279-86-6 Methyl 3-[3-(2-{[2-(methyloxy)-4-(4-morpholinyl)phenyl]amino}-4-pyrimidinyl)-imidazo[1,2-a]pyridin-2-yl]benzoate 
• 1042672-97-8 C₂₀H₂₀N₄O₃S 
• 1184931-49-4 4-iodo-5-methyl-N-[2-(methyloxy)-4-(4-morpholinyl)phenyl]-2-pyridinamine 
• 1184931-51-8 5-chloro-4-iodo-N-[2-(methyloxy)-4-(4-morpholinyl)phenyl]-2-pyridinamine 
• 1061353-68-1 2-(2-(2-methoxy-4-morpholinophenylamino)-5-(trifluoromethyl)pyridin-4-ylamino)-N-methylbenzamide 
• 1061355-87-0 2-[(5-bromo-2-{[2-(methyloxy)-4-(4-morpholinyl)phenyl]amino}-4-pyridinyl)amino]-N-methylbenzamide 
• 1184931-55-2 2-[(5-chloro-2-{[2-(methyloxy)-4-(4-morpholinyl)phenyl]amino}-4-pyridinyl)amino]benzoic acid 
• 1184931-44-9 2-[5-cyclopropyl-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyridin-4-ylamino]-N-methoxy-benzamide 
• 1184931-46-1 2-[5-cyclopropyl-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyridin-4-ylamino]-N-methyl-benzamide 
• 1184931-47-2 2-[2-(2-methoxy-4-morpholin-4-yl-phenylamino)-5-vinyl-pyridin-4-ylamino]-N-methyl-benzamide 
• 1097916-78-3 2-(4-(2-methoxy-4-morpholinophenylamino)-1,3,5-triazin-2-ylamino)-N-methylbenzamide 

Relevant articles and documents

Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer

NUAK, the member of AMPK (AMP-activated protein kinase) family of protein kinases, is phosphorylated and activated by the LKB1 (liver kinase B1) tumor suppressor protein kinase. Recent work has indicated that NUAK1 is a key component of the antioxidant stress response pathway, and the inhibition of NUAK1 will suppress the growth and survival of colorectal tumors. As a promising target for anticancer drugs, few inhibitors of NUAK were developed. With this goal in mind, based on NUAK inhibitor WZ4003, a series of derivatives has been synthesized and evaluated for anticancer activity. Compound 9q, a derivative of WZ4003 by removing a methoxy group, was found to be the most potential one with stronger inhibitory against NUAK1/2 enzyme activity, tumor cell proliferation and inducing apoptosis of tumor cells. By in vivo efficacy evaluations of colorectal SW480 xenografts, 9q suppresses tumor growth more effectively with an excellent safety profile in vivo and is therefore seen as a suitable candidate for further investigation.

COMPOUNDS AND THEIR USES AS MIF INHIBITORS

The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the i

Design, synthesis and biological evaluation of novel pteridinone derivatives as potent dual inhibitors of PLK1 and BRD4

To develop novel simultaneous inhibition of PLK1 and BRD4 bromodomain by a single molecule, three series of novel pteridinone derivatives were designed, synthesized and evaluated for their biological activity. Most compounds exhibited moderate to excellent cytotoxic activity against A549, HCT116, PC-3 and MCF-7 cell lines. The most promising compound III4 showed high antiproliferative effects on four cell lines with IC50 values of 1.27 μM, 1.36 μM, 3.85 μM and 4.06 μM, respectively. The enzymatic assay identified III4 as a potent PLK1 and BRD4 dual inhibitor with % inhibition values of 96.6 and 59.1, respectively. Furthermore, to clarify the anticancer mechanism of the target compounds, explorations in the bioactivity were conducted. The results showed that compound III4 obviously inhibited the proliferation of HCT-116 cell lines, induced a great decrease in the mitochondrial membrane potential leading to apoptosis of cancer cells, suppressed the migration of tumor cells, and arrested the S phase of HCT116 cells.